AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

QGEN · NYSE · Medical - Diagnostics & Research

QIAGEN (QGEN)

Supplies sample technologies, molecular diagnostics, PCR and genomics tools for research and clinical testing.

$43.69

After hours0.00 (0.00%)

At close$43.69(−2.43%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	476	509	459	496	502	521	483	534	533	540	492	535
Cost of revenue	178	193	168	462	194	188	175	199	201	223	183	195
Gross profit	298	316	291	35	308	333	309	334	331	317	310	340
	201	205	196	263	196	214	193	212	202	163	193	208
Research & development	48	46	51	49	44	49	44	48	49	47	48	50
	140	146	139	143	141	142	138	149	143	154	142	147
Selling & marketing	111	117	111	115	111	114	106	118	113	121	115	117
General & administrative	29	28	28	29	29	28	32	31	30	33	28	30
Other expenses	13	14	6	71	11	24	12	16	10	−38	2	11
Operating income	97	111	95	−228	112	119	115	122	129	154	117	132
	3	8	7	5	4	7	4	5	6	−45	−31	0
Interest income	20	19	18	17	18	15	15	14	15	20	11	9
Interest expense	13	12	10	11	11	11	7	8	8	10	11	10
Other non-operating income	−16	−21	−18	−16	−16	−18	−11	−13	−14	35	20	−10
Income before tax	100	119	102	−223	116	126	120	127	135	109	86	132
Income tax expense	22	21	22	−40	18	38	29	31	5	1	18	29
Net income from continuing operations	78	98	81	−183	98	88	91	96	130	108	68	103
Net income	78	98	81	−183	98	88	91	96	130	108	68	103
EPS, basic	$0.35	$0.44	$0.36	−$0.83	$0.44	$0.41	$0.42	$0.44	$0.60	$0.52	$0.33	$0.50
EPS, diluted	$0.35	$0.44	$0.36	−$0.83	$0.44	$0.41	$0.41	$0.44	$0.60	$0.52	$0.33	$0.50
Weighted average shares, basic	221	221	224	222	222	216	218	217	217	208	207	206
Weighted average shares, diluted	224	224	227	222	224	218	220	218	218	208	209	208
EBITDA	163	183	167	−159	178	183	171	184	277	169	148	142
Depreciation & amortization	51	52	54	53	50	46	44	49	134	49	51	0
EBIT	113	131	113	−213	128	137	127	134	143	119	97	142